Retrospective Study
Copyright ©The Author(s) 2016.
World J Gastroenterol. Mar 14, 2016; 22(10): 3015-3022
Published online Mar 14, 2016. doi: 10.3748/wjg.v22.i10.3015
Table 1 Comparison of patients’ characteristics and surgical outcomes n (%)
LLR (n = 39)OLR (n = 29)P value
Age (yr)69.4 ± 10.268.3 ± 8.1NS
Sex (Male/Female)26/1322/7NS
HBV6 (15.4)4 (13.8)NS
HCV19 (48.7)13 (44.8)NS
Diagnosis
Hepatocellular carcinoma33 (84.6)22 (75.9)
Intrahepatic cholangiocarcinoma2 (5.1)1 (3.4)
Metastatic liver tumor2 (5.1)6 (20.7)
Hemangioma2 (5.1)0
Body mass index (kg/m2)24.1 ± 4.123.9 ± 3.9NS
Tumor size (mm)27.3 ± 14.527.6 ± 11.6NS
Surgical outcome
Operation time (min)226.1 ± 117.2292.8 ± 86.70.009
Blood loss (mL)109.3 ± 162.0406.9 ± 425.60.001
Postoperative hospital stay (d)12.8 ± 10.423.6 ± 30.10.042
Overall morbidity4 (10.2)7 (24.1)NS
Grade I01
Grade II34
Grade III (a/b)1/01/1
Grade IV00
Grade V00
Bile leakage1 (2.7)2 (6.9)NS
Table 2 Comparison of patients’ characteristics and surgical outcomes in patients with obesity
LLR (n = 12)OLR (n = 10)P value
Patients’ characteristics
Age70.5 ± 9.467.1 ± 6.2NS
Sex (Male/Female)7/510/00.020
HBV12NS
HCV72NS
Body mass index (kg/m2)29.0 ± 3.728.2 ± 2.3NS
Tumor size (mm)23.8 ± 8.726.0 ± 11.6NS
Liver weight (g)47.1 ± 35.560.8 ± 61.2NS
Surgical outcome
Operation time (min)241.3 ± 97.6346.7 ± 83.80.014
Blood loss (mL)128.3 ± 193.1635.5 ± 655.10.039
Postoperative hospital stay (d)11.6 ± 3.320.8 ± 15.40.094
Complication, n (%)1 (8.3)1 (10)NS
Biloma00NS
Table 3 Univariate and multivariate analysis on prolonged operation time
Operation time
UnivariateMultivariate
< 200200P valueP valueOR (95%CI)
Number of patients2543
Age (yr)71.5 ± 8.467.4 ± 9.60.082
Sex (Male/Female)16/932/110.363
Body mass index (kg/m2)22.7 ± 2.624.8 ± 4.50.0190.0241.259 (1.031-1.538)
HBV280.304
HCV12200.906
Open liver resection < 0.001326< 0.001< 0.00116.244 (3.648-72.340)
Tumor size (mm)23.3 ± 9.929.8 ± 14.40.0490.0471.056 (1.001-1.114)
Total bilirubin (mg/dL)0.77 ± 0.280.79 ± 0.310.829
Albumin (g/dL)3.94 ± 0.593.91 ± 0.460.848
Prothrombin time (%)101.4 ± 21.998.2 ± 17.20.508
Indocyanine green (%)11.8 ± 11.118.9 ± 14.80.042
Aspartate transaminase (U/L)36.8 ± 20.539.1 ± 20.90.669
Alanine transaminase (U/L)30.2 ± 22.833.3 ± 22.30.596
γ-glutamy transpeptidase (U/L)57.5 ± 48.364.8 ± 51.30.567
Alkaline phosphatase (U/L)315.6 ± 109.9306.0 ± 105.50.725
Cholinesterase (U/L)176.6 ± 127.0188.5 ± 115.30.649
White blood cell (/mm3)4342 ± 13834638 ± 17480.470
Hemoglobin (g/dL)12.8 ± 1.913.1 ± 2.10.598
Hematocrit (%)36.9 ± 7.339.0 ± 5.60.185
Platelet count (× 103/mm3)14.5 ± 7.713.2 ± 6.00.433
Table 4 Univariate and multivariate analysis on increased blood loss
Blood loss
UnivariateMultivariate
< 215215P valueP valueOR (95%CI)
Number of patients4028
Age (yr)68.5 ± 10.168.1 ± 4.50.558
Sex (Male/Female)26/1422/60.227
Body mass index (kg/m2)23.1 ± 3.425.3 ± 4.50.0270.0351.233 (1.015-1.498)
HBV460.297
HCV20120.561
Open liver resection821< 0.001< 0.00127.736 (5.926-129.811)
Tumor size (mm)26.0 ± 11.429.4 ± 15.50.303
Total bilirubin (mg/dL)0.76 ± 0.300.81 ± 0.300.490
Albumin (g/dL)3.98 ± 0.553.84 ± 0.430.287
Prothrombin time (%)103.2 ± 20.393.9 ± 15.60.0460.0300.947 (0.902-0.995)
Indocyanine green (%)13.4 ± 10.720.3 ± 16.90.044
Aspartate transaminase (U/L)34.3 ± 19.843.9 ± 20.70.056
Alanine transaminase (U/L)28.3 ± 19.637.6 ± 25.20.955
γ-glutamy transpeptidase (U/L)52.6 ± 50.175.7 ± 47.40.060
Alkaline phosphatase (U/L)310.1 ± 107.1308.6 ± 107.30.955
Cholinesterase (U/L)178.9 ± 130.0191.6 ± 103.00.669
White blood cell (/mm3)4339 ± 15404802 ± 17160.249
Hemoglobin (g/dL)12.8 ± 1.913.4 ± 2.20.218
Hematocrit (%)37.0 ± 6.540.0 ± 5.70.056
Platelet count (× 103/mm3)14.7 ± 7.612.3 ± 4.60.114